Pigmented basal cell carcinoma successfully treated with 5% imiquimod cream

Abstract

Basal cell carcinoma (BCC) is the most common malignant skin tumor, amongst which the nodular, nodulo ulcerative and superficial types comprise nearly 80% of all BCCs. Topical Imiquimod, an immune response modifier has been found to be effective in superficial and nodular types of BCC with histological clearance rates of up to 100%. We report our experience of treatment a large pigmented BCC on the face with topical Imiquimod 5% cream.

Keywords

• <i>Basal cell carcinoma
• pigmented
• treatment
• Imiquimod </i>